Danielle Brill
Stock Analyst at Raymond James
(2.10)
# 2,969
Out of 4,981 analysts
83
Total ratings
41.67%
Success rate
-4.53%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Initiates: Market Perform | n/a | $394.18 | - | 3 | Sep 3, 2025 | |
| IRON Disc Medicine | Initiates: Buy | $86 | $60.10 | +43.09% | 6 | Jul 21, 2025 | |
| ALNY Alnylam Pharmaceuticals | Initiates: Buy | $385 | $469.10 | -17.93% | 1 | Jul 21, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $48 | $32.34 | +48.45% | 8 | Jul 21, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Buy | $56 | $56.50 | -0.88% | 1 | Jul 21, 2025 | |
| TECX Tectonic Therapeutic | Initiates: Buy | $64 | $17.91 | +257.34% | 2 | Jul 21, 2025 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $163 | $142.23 | +14.61% | 6 | Jul 21, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Buy | $66 | $51.40 | +28.40% | 1 | Jul 21, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Buy | $30 | $21.57 | +39.08% | 1 | Jul 21, 2025 | |
| JCAP Jefferson Capital | Initiates: Buy | $24 | $18.34 | +30.86% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $20 → $52 | $16.67 | +211.94% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $14.35 | - | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $79 | $54.28 | +45.54% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $18 | $9.22 | +95.27% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $36 | $16.25 | +121.54% | 4 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $150 | $17.34 | +765.05% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $145.27 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $761.64 | -20.57% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $23.48 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $36.37 | +37.48% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $36.81 | +38.55% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $180 → $100 | $7.00 | +1,328.57% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $60.89 | - | 9 | Sep 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.03 | - | 5 | Jun 27, 2023 |
Vertex Pharmaceuticals
Sep 3, 2025
Initiates: Market Perform
Price Target: n/a
Current: $394.18
Upside: -
Disc Medicine
Jul 21, 2025
Initiates: Buy
Price Target: $86
Current: $60.10
Upside: +43.09%
Alnylam Pharmaceuticals
Jul 21, 2025
Initiates: Buy
Price Target: $385
Current: $469.10
Upside: -17.93%
Harmony Biosciences Holdings
Jul 21, 2025
Initiates: Buy
Price Target: $48
Current: $32.34
Upside: +48.45%
Palvella Therapeutics
Jul 21, 2025
Initiates: Buy
Price Target: $56
Current: $56.50
Upside: -0.88%
Tectonic Therapeutic
Jul 21, 2025
Initiates: Buy
Price Target: $64
Current: $17.91
Upside: +257.34%
Neurocrine Biosciences
Jul 21, 2025
Initiates: Buy
Price Target: $163
Current: $142.23
Upside: +14.61%
BridgeBio Pharma
Jul 21, 2025
Initiates: Buy
Price Target: $66
Current: $51.40
Upside: +28.40%
Centessa Pharmaceuticals
Jul 21, 2025
Initiates: Buy
Price Target: $30
Current: $21.57
Upside: +39.08%
Jefferson Capital
Jul 21, 2025
Initiates: Buy
Price Target: $24
Current: $18.34
Upside: +30.86%
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $16.67
Upside: +211.94%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $14.35
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $54.28
Upside: +45.54%
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $9.22
Upside: +95.27%
Oct 10, 2024
Reinstates: Outperform
Price Target: $36
Current: $16.25
Upside: +121.54%
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $17.34
Upside: +765.05%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $145.27
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $761.64
Upside: -20.57%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $23.48
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $36.37
Upside: +37.48%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $36.81
Upside: +38.55%
Nov 14, 2023
Maintains: Outperform
Price Target: $180 → $100
Current: $7.00
Upside: +1,328.57%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $60.89
Upside: -
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $12.03
Upside: -